Highest-materiality recent filing
Genelux stockholders re-elect John Smither as Class I director, ratify Weinberg & Co. as auditor
John Smither re-elected as Class I director: 8,696,891 for, 3,393,408 withheld, 16,172,901 broker non-votes.
Genelux enters $100M at-the-market equity offering agreement with TD Cowen
Sales Agreement with TD Cowen allows offering of common stock up to $100M aggregate.
Genelux furnishes updated corporate presentation; no specifics disclosed
Presentation dated February 2026 includes business and strategic updates.
Genelux prices $20M public offering of 6.7M shares at $3.00
Priced underwritten public offering of 6,666,667 shares at $3.00 each.
Genelux reports 33% ORR in SCLC and 60% DCR in NSCLC with systemic Olvi-Vec
SCLC Phase 1b/2: 33% ORR (3/9 PRs), 67% DCR; highest dose cohort 67% ORR (2/3) with tumor shrinkage ~55% and ~85%.
Genelux appoints Jason Litten as CMO after Paul Scigalla resigns
Paul Scigalla, M.D., resigned as CMO effective December 30, 2025.
Genelux reprices employee stock options to $3.33 from up to $22.40; covers 2.7M shares
Exercise price reduced to $3.33 for eligible options with prior range $6.00–$22.40 per share.
Genelux reports preliminary cash ~$30.9M; positive Olvi-Vec SCLC data and FDA guidance for PRROC
Preliminary cash, cash equivalents, and short-term investments as of Dec 31, 2024: ~$30.9M (unaudited).
Genelux prices $10.5M underwritten offering of 3M shares at $3.50/share
Gross proceeds of $10.5M from 3,000,000 shares at $3.50 per share; closing expected March 26, 2025.
Genelux CFO Lourie Zak resigns; Matt Pulisic appointed CFO with $410k salary, 275k option
Lourie Zak resigned as CFO effective Jan 29, 2025; separation includes $180k cash payment (6 months salary) and advisory role through Aug 29, 2025.
Genelux made available a corporate presentation for use in investor and analyst meetings.
Genelux VP of Quality Caroline Jewett resigns effective Oct 18, 2024
Caroline Jewett resigned as VP, Head of Quality, effective October 18, 2024.
Genelux holds 2024 annual meeting; elects two Class II directors
Elected Mary Mirabelli as Class II director with 13,349,192 votes for, 1,386,089 withheld, and 7,740,438 broker non-votes.
Genelux posts corporate presentation on August 1, 2024; no specific new data disclosed in filing
Furnished corporate presentation as Exhibit 99.1 under Regulation FD.
Genelux receives ~$2.35M net from partial overallotment exercise by underwriters
Underwriters exercised option to purchase 625,000 shares and warrants at $4.00 per unit.
Genelux prices $27.5M offering of 6.875M shares and warrants at $4.00
Gross proceeds ~$27.5M; net ~$25.4M from 6,875,000 shares and 6,875,000 warrants at combined $4.00/unit.
Genelux files corporate presentation; no specific financial data disclosed
Presentation dated April 9, 2024 covers company overview and strategy.
Genelux makes corporate presentation available; no material updates in text
Company furnished a corporate presentation under Regulation FD on April 1, 2024.
Genelux provides corporate presentation; content not summarized in filing
Corporate presentation made available on February 5, 2024, for investor meetings.
Genelux estimates Dec 31, 2023 cash at ~$23.2M, preliminary and unaudited
Cash, cash equivalents and short-term investments estimated at approximately $23.2 million as of December 31, 2023.
Genelux posts corporate slide presentation; no specific news disclosed
Company issued a corporate slide presentation on December 12, 2023 via Item 7.01.
Genelux VP of Finance Doug Samuelson resigns effective Nov 21, 2023
Doug Samuelson resigned as VP, Finance, effective immediately on November 21, 2023.
Genelux files 8-K with corporate presentation; no material new details provided
Corporate presentation made available as Exhibit 99.1 but content not disclosed in filing body.
Genelux adopts 2023 Inducement Plan reserving 1M shares; John Smither elected director
Board approved 2023 Inducement Plan reserving 1,000,000 shares for new-hire equity awards as inducement material under Nasdaq Listing Rule 5635(c)(4).
Genelux appoints Lourie Zak as CFO effective August 28, 2023
Lourie Zak named CFO, principal financial officer, and principal accounting officer.
Genelux: Olvi-Vec estimated billion+ US market; interim data in recurrent NSCLC expected mid-2024
Olvi-Vec estimated to represent more than $1 billion annual US market opportunity.
Director Gabe Woodward resigns; Genelux audit committee size fails Nasdaq rule
Gabe Woodward resigned from the Board effective July 12, 2023, at request of his partnership after IPO completion.
Genelux provides Phase 3 enrollment timeline for Olvi-Vec and cash runway into Q1 2026
Enrollment for Phase 3 trial of Olvi-Vec in platinum-resistant/refractory ovarian cancer expected to complete mid-2024 with 11-month follow-up.
Genelux Corp raises ~$18M in private placement of 900K shares at $20/share
Gross proceeds ~$18M from sale of 900K shares of common stock at $20 per share.
Genelux formalizes CEO Thomas Zindrick employment agreement with $595K salary, bonus, and severance
Base salary set at $595,000 per year effective April 1, 2023.
Genelux closes $15M IPO at $6.00/share; reprices stock options to IPO price
IPO of 2,500,000 shares at $6.00/share closed Jan 30, 2023; gross proceeds ~$15M.
On February 3, 2025, the Company announced the appointment of Matt Pulisic as the Company’s Chief Financial Officer, effective as of January 30, 2025 (the “ Effective Date ”).
On January 29, 2025 (the “ Separation Date ”), Lourie Zak resigned as Chief Financial Officer of Genelux Corporation (the “ Company ”), effective immediately.
On September 23, 2024, Caroline Jewett notified Genelux Corporation (the “Company”) of her resignation as Vice President, Head of Quality of the Company, effective as of October 18, 2024.
On November 21, 2023, Doug Samuelson resigned as VP, Finance of Genelux Corporation effective as of November 21, 2023.
Thomas Zindrick, the Company’s President and Chief Executive Officer, will no longer serve as the Company’s principal financial officer
Doug Samuelson, the Company’s former Chief Financial Officer, will no longer serve as the Company’s principal accounting officer
On August 28, 2023, Genelux Corporation (the “ Company ”) announced the appointment of Lourie Zak as the Company’s Chief Financial Officer and the designation of Ms. Zak as the Company’s principal financial officer and principal accounting officer
Gabe Woodward notified the board of directors (the “Board”) of Genelux Corporation (the “Company”) of his decision to resign from the Board, effective July 12, 2023.
Max materiality 0.85 · Median 0.50 · Most common event other_material